A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2018
At a glance
- Drugs Exenatide (Primary) ; Empagliflozin; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms FREEDOM-4-OAD
- Sponsors Intarcia Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 27 Jan 2018 Status changed from active, no longer recruiting to discontinued as per sponsors decision.
- 08 Nov 2017 This trial has beeen completed in Netherlands.